在阿尔茨海默病中使用SPYTACs有效降解粉样β
Fei Teng1, Jing Liu2, Tongtong Cui2
1Medical School, University of Chinese Academy of Sciences, Beijing 100049, China.
Cell
|March 5, 2026
概括
新的SPYTACs在阿尔茨海默氏症模型中有效清除粉样β (Aβ),副作用比免疫疗法少. 这个平台为治疗与蛋白质相关的疾病提供了一种有前途,多功能的方法.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药物发现 药物发现 药物发现
背景情况:
- 阿尔茨海默病 (AD) 治疗的目的是清除粉样β (Aβ) 斑块.
- 目前的抗Aβ免疫疗法存在安全问题和不良影响.
- 细胞外向蛋白降解 (eTPD) 为蛋白质清除提供了一个更安全的替代方案.
研究的目的:
- 开发一个新的eTPD平台,SPYTACs,以有效和安全地清除细胞外蛋白质.
- 在AD小鼠模型中评估SPYTACs在降低Aβ负担和改善认知功能的有效性.
- 与传统免疫疗法相比,评估SPYTACs的安全性.
主要方法:
- 使用两种特异性的合成编程 lysosome-targeting 嵌合体 (SPYTACs) 的开发.
- 利用低密度脂蛋白受体相关蛋白1 (LRP1) 进行向蛋白质降解和转细胞.
- 在5×FAD小鼠体内给予SPYTACs,用于AD的前兆和症状阶段.
主要成果:
- 在5×FAD小鼠中,SPYTAC有效地降低了外周和大脑Aβ负担.
- 治疗减轻了突触损失,改善了认知功能.
- 与免疫疗法相比,SPYTACs表现出良好的安全性,减少了脑内出血和炎症的发生率.
结论:
- SPYTACs代表了下一代eTPD平台,具有针对阿尔茨海默病的治疗潜力.
- 该平台的模块化和遗传编码性允许针对各种引起疾病的蛋白质.
- SPYTACs为蛋白质病变提供了一个有希望的,更安全的治疗策略.
关键词:
AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD AD ADD was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was was阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.亚博体育在线娱乐 亚博体育在线娱乐在SPYTAC中,我们可以看到.粉样化物-β-β 的存在.在eTPD中使用eTPD.细胞外向蛋白质降解的向蛋白质降解
相关概念视频
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
03:03Amyloid Fibrils
6.8K
6.8K
03:03Amyloid Fibrils
12.4K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.4K
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K